Home/Transcenta Therapeutics/Xueming Qian, PhD

XQ

Xueming Qian, PhD

Chairman and CEO

Transcenta Therapeutics

Therapeutic Areas

Oncology Musculoskeletal Renal

Transcenta Therapeutics Pipeline

Drug	Indication	Phase
Osemitamab (TST001)	Gastric/Gastroesophageal Junction (G/GEJ) Cancer	Phase 2/3
TST002 (Blosozumab)	Osteoporosis	Phase 1
TST003	Solid Tumors	Phase 1

Leadership Team at Transcenta Therapeutics

CMO & EVP, Head of Global R&D

Weiwei Liang, MBA

Acting CFO, SVP, Business Development Transaction & Corporate Strategy

View full Transcenta Therapeutics profile